Engineered peptides open new avenue for immunotherapy drug development

In a new study published in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have designed a new method for developing immunotherapy drugs using engineered peptides to elicit a natural immune response inside the body.

Leave A Comment

Your email address will not be published. Required fields are marked *